Ascendis Pharma A/S (NASDAQ:ASND) Receives $192.07 Average PT from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $192.07.

Several research analysts have issued reports on the company. JPMorgan Chase & Co. cut their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Wells Fargo & Company upped their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Finally, Citigroup upped their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th.

Ascendis Pharma A/S Price Performance

ASND stock opened at $129.19 on Thursday. The company’s 50-day moving average is $132.61 and its 200-day moving average is $133.58. The stock has a market capitalization of $7.84 billion, a PE ratio of -15.99 and a beta of 0.65. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ASND. Signaturefd LLC raised its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the period. Profund Advisors LLC increased its position in Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after buying an additional 85 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $30,000. Finally, GAMMA Investing LLC lifted its position in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.